Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (363)	1/12/2001 1:12:47 AM
From: Dr. Voodoo	Respond to of 1784

Hi Tuck, ionspec.com Here's a good site for understanding the basics of FTICR-MS. FTICR is what I think is going to change drug screening in the near future. They are able to put a protein or other biomolecule in a tube with a mixture of up to 100 small molecules and look for binding. The ability to achieve ppm mass resolution enables a high resolution mass(which really narrows down compounds from a list of a 100 or so masses which one or two is the binder). By placing a native ligand in the mix as well, one can look for competitive binding of such a small molecule and determine site specificity. Regards, V